TUMI Genomics: Next Generation Sequencing (NGS) Diagnosis for COVID-19

closed

The solution proposed in this grant will increase the diagnostic capacity in Peru for SARS-CoV-2 and introduce a dramatically more sensitive and precise test than current tests (see additional information). Therefore, the immediate beneficiaries of our solution would be the Peruvian population, as well as the public health entities that are currently dealing with an accumulation of diagnostic tests. The world population will also benefit from our solution, as the data we collect in Peru can be used to track the evolution and movement of SARS-CoV-2 allowing effective containment of the pandemic. Long-term beneficiaries include the international community of drug researchers and developers who could use the viral genomic data collected by Tumi Genomics to reveal the molecular epidemiology and evolution of the SARS-CoV-2 virus and guide effective treatment.